Pioglitazone attenuates complement-mediated microglial synaptic engulfment in an Alzheimer’s disease model
Brain · 07.02.2026 · 149 (2) · 668-679
DOI: 10.1093/brain/awaf462 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain, online erschienen am 15.12.2025. Verfasst von Juan Zu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Center for Neuropathology and Prion Research, Ludwig Maximilian University of Munich, Munich 81377, Germany. Hauptthemen laut MEDLINE: Pioglitazone, Alzheimer Disease, Microglia, Synapses. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Verein zur Förderung von Wissenschaft und Forschung an der Medizinischen Fakultät der LMU München.
Themen: Demenz
Abstract (Originalsprache)
Synaptic loss is an early hallmark of Alzheimer’s disease (AD), predominantly driven by aberrant microglial reactivity. Pioglitazone, a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist with anti-diabetic properties, has been shown to suppress microglial activity and improve cognitive performance in both AD models and clinical studies. However, whether its neuroprotective effects involve direct modulation of synaptic architecture remains unclear. Here, using longitudinal in vivo two-photon imaging, multi-channel immunohistochemistry, super-resolution confocal microscopy and three-dimensional reconstruction techniques in an AD mouse model, we analyse synaptic and microglial interactions. We show that a 4-week pioglitazone treatment preserves dendritic spine density and enhances spine stability over time. Mechanistically, pioglitazone reduces synaptic C1q deposition, thereby limiting complement-mediated microglial synaptic engulfment and attenuating synapse loss. These findings identify pioglitazone as a modulator of complement-dependent microglial synaptic pruning and support its therapeutic potential in preserving synaptic integrity during early AD pathogenesis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Neuropathology and Prion Research, Ludwig Maximilian University of Munich, Munich 81377, Germany.
- German Center for Neurodegenerative Diseases (DZNE), Munich 81377, Germany.
- Munich Medical Research School, Ludwig Maximilian University of Munich, Munich 80331, Germany.
- Department of Medicine IV, University Hospital, Ludwig Maximilian University of Munich, Munich 80331, Germany.
- Munich Cluster for Systems Neurology (SyNergy), Munich 81377, Germany.
ORCID-Profile: Mochen Cui, Xinwu Liu, Zhouyang Pan, Xiaohe Li, Yuan Shi
Förderung
- Deutsche Forschungsgemeinschaft
- Verein zur Förderung von Wissenschaft und Forschung an der Medizinischen Fakultät der LMU München
Zitieren
APA
Zu, J., Li, C., Cui, M., Liu, X., Pan, Z., Li, X., Zhang, F., Gentz, J., Mitteregger-Kretzschmar, G., Herms, J., & Shi, Y. (2026). Pioglitazone attenuates complement-mediated microglial synaptic engulfment in an Alzheimer’s disease model. Brain, 149(2), 668-679. https://doi.org/10.1093/brain/awaf462
Vancouver
Zu J, Li C, Cui M, Liu X, Pan Z, Li X, et al. Pioglitazone attenuates complement-mediated microglial synaptic engulfment in an Alzheimer’s disease model. Brain. 2026;149(2):668-679. doi:10.1093/brain/awaf462
BibTeX
@article{Zu2026,
author = {Zu, Juan and Li, Cong and Cui, Mochen and Liu, Xinwu and Pan, Zhouyang and Li, Xiaohe and Zhang, Fang and Gentz, Johanna and Mitteregger-Kretzschmar, Gerda and Herms, Jochen and Shi, Yuan},
title = {Pioglitazone attenuates complement-mediated microglial synaptic engulfment in an Alzheimer’s disease model},
journal = {Brain},
year = {2026},
volume = {149},
number = {2},
pages = {668--679},
doi = {10.1093/brain/awaf462}
}
EUVIMED